Drug intelligence / Profile preview

MBTC-IgP-EVs

Development stage: Preclinical
Lead developer: Stemmedicare
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

MBTC-IgP-EVs is an extracellular vesicle (EV)-based vaccine adjuvant platform developed by Stemmedicare. It is designed to enhance the immune response to vaccines for infectious diseases, including COVID-19, influenza, and tuberculosis. The platform utilizes EVs that are claimed to be non-immunogenic or immune-tolerized, potentially reducing adverse reactions while improving the efficacy of the co-administered vaccine. As of the current pipeline status, the candidate is in the research and efficacy verification stage, focusing on its potential as a versatile adjuvant for various viral and bacterial pathogens.

Other names: MBTC-IgP-EVs (Vaccine Adjuvant)

Beyond the preview

Go deeper on MBTC-IgP-EVs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBTC-IgP-EVs.

Explore the full profile